- Home
- CMPR vs BEAM Comparison
CMPR vs BEAM Comparison
Compare CMPR & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPR
- BEAM
- Stock Information
- Founded
- CMPR 1994
- BEAM 2017
- Country
- CMPR Ireland
- BEAM United States
- Employees
- CMPR N/A
- BEAM N/A
- Industry
- CMPR Publishing
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CMPR Consumer Discretionary
- BEAM Health Care
- Exchange
- CMPR Nasdaq
- BEAM Nasdaq
- Market Cap
- CMPR 1.1B
- BEAM 1.6B
- IPO Year
- CMPR N/A
- BEAM 2020
- Fundamental
- Price
- CMPR $49.68
- BEAM $20.01
- Analyst Decision
- CMPR Strong Buy
- BEAM Strong Buy
- Analyst Count
- CMPR 2
- BEAM 11
- Target Price
- CMPR $62.50
- BEAM $48.90
- AVG Volume (30 Days)
- CMPR 321.9K
- BEAM 2.0M
- Earning Date
- CMPR 07-30-2025
- BEAM 08-05-2025
- Dividend Yield
- CMPR N/A
- BEAM N/A
- EPS Growth
- CMPR 83.61
- BEAM N/A
- EPS
- CMPR 5.97
- BEAM N/A
- Revenue
- CMPR $3,366,207,000.00
- BEAM $63,578,000.00
- Revenue This Year
- CMPR $4.65
- BEAM N/A
- Revenue Next Year
- CMPR $3.16
- BEAM $8.82
- P/E Ratio
- CMPR $8.33
- BEAM N/A
- Revenue Growth
- CMPR 3.64
- BEAM N/A
- 52 Week Low
- CMPR $35.21
- BEAM $13.53
- 52 Week High
- CMPR $104.92
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- CMPR 66.92
- BEAM 68.31
- Support Level
- CMPR $45.78
- BEAM $16.59
- Resistance Level
- CMPR $50.82
- BEAM $17.38
- Average True Range (ATR)
- CMPR 1.96
- BEAM 1.10
- MACD
- CMPR 0.52
- BEAM 0.35
- Stochastic Oscillator
- CMPR 87.00
- BEAM 89.70
About CMPR Cimpress plc (Ireland)
Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.